A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Conditions
Malignant Neoplasm
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Rutgers Cancer Institute of New Jersey ( Site 0052), New Brunswick, New Jersey, United States
NEXT Oncology ( Site 0051), Irving, Texas, United States
NEXT Virginia ( Site 0054), Fairfax, Virginia, United States
Blacktown Hospital ( Site 0455), Sydney, New South Wales, Australia
Monash Health ( Site 0452), Clayton, Victoria, Australia
The Alfred Hospital ( Site 0453), Melbourne, Victoria, Australia
One Clinical Research ( Site 0454), Nedlands, Western Australia, Australia
Princess Margaret Cancer Centre ( Site 0001), Toronto, Ontario, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0002), Québec, Quebec, Canada
Pontificia Universidad Catolica de Chile-CICUC ( Site 0103), Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0102), Santiago, Region M. de Santiago, Chile
Rambam Health Care Campus ( Site 0252), Haifa, Israel
Rabin Medical Center ( Site 0253), Petah Tikva, Israel
Sheba Medical Center ( Site 0251), Ramat Gan, Israel
Seoul National University Hospital ( Site 0501), Seoul, South Korea
Asan Medical Center ( Site 0502), Seoul, South Korea
Hospital General Universitari Vall d Hebron ( Site 0360), Barcelona, Spain
Hospital Clinic de Barcelona ( Site 0362), Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz ( Site 0361), Madrid, Spain
Study leads
Medical Director
Study Director
Merck Sharp & Dohme LLC